
GSK269962A
CAS No. 850664-21-0
GSK269962A( GSK 269962 )
Catalog No. M17614 CAS No. 850664-21-0
GSK269962 is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 47 | In Stock |
![]() ![]() |
5MG | 74 | In Stock |
![]() ![]() |
10MG | 138 | In Stock |
![]() ![]() |
25MG | 291 | In Stock |
![]() ![]() |
50MG | 431 | In Stock |
![]() ![]() |
100MG | 619 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameGSK269962A
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK269962 is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.
-
DescriptionGSK269962 is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.
-
In Vitro——
-
In VivoAnimal Model:Male Sprague-Dawley rats (350-400g)Dosage:0.3, 1, and 3 mg/kg Administration:Oral gavage; 12 hours Result:Induced a dose-dependent reduction in blood pressure.
-
SynonymsGSK 269962
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorMSK1| ROCK1| ROCK2| RSK1
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number850664-21-0
-
Formula Weight570.61
-
Molecular FormulaC29H30N8O5
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 30 mg/mL; 52.58 mM
-
SMILESCCn1c2cc(ncc2nc1c1nonc1N)Oc1cccc(c1)NC(=O)c1ccc(cc1)OCCN1CCOCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Doe C, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. Epub 2006 Oct 3.
molnova catalog



related products
-
Lenvatinib
Lenvatinib (E7080) is a multitargeted kinase inhibitor with IC50s of 4/5.2/22/46 nM for VEGFR2/VEGFR3/VEGFR1/FGFR1 in cell free assays.
-
Pamufetinib mesylate
Pamufetinib mesylate (TAS-115 mesylate) is a potent vascular endothelial growth factor receptor (VEGFR) antagonist and hepatocyte growth factor receptor (c-Met) inhibitor used in the study of cancer and respiratory diseases.
-
Regorafenib hydrochl...
Regorafenib hydrochloride (BAY73-4506) is a potent, orally active multikinase inhibitor.